RU2695358C2 - Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли - Google Patents

Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли Download PDF

Info

Publication number
RU2695358C2
RU2695358C2 RU2016118282A RU2016118282A RU2695358C2 RU 2695358 C2 RU2695358 C2 RU 2695358C2 RU 2016118282 A RU2016118282 A RU 2016118282A RU 2016118282 A RU2016118282 A RU 2016118282A RU 2695358 C2 RU2695358 C2 RU 2695358C2
Authority
RU
Russia
Prior art keywords
pain
adenosine
compound
mice
methyl
Prior art date
Application number
RU2016118282A
Other languages
English (en)
Russian (ru)
Other versions
RU2016118282A (ru
RU2016118282A3 (enExample
Inventor
Джим-Минь ФАН
Юн-Лянь ЛИН
Чжун-Синь ЛИН
Чун-Чжун ЛИН
Ичжуан ЧЕРН
Най-Куэй ХУАН
Хун-Ли ВАН
Бенджамин Пан-Сянь ТУ
Чи-Чэн ЧЭНЬ
Original Assignee
Академия Синика
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Академия Синика filed Critical Академия Синика
Publication of RU2016118282A publication Critical patent/RU2016118282A/ru
Publication of RU2016118282A3 publication Critical patent/RU2016118282A3/ru
Application granted granted Critical
Publication of RU2695358C2 publication Critical patent/RU2695358C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
RU2016118282A 2013-10-23 2014-10-22 Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли RU2695358C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
US61/894,699 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (3)

Publication Number Publication Date
RU2016118282A RU2016118282A (ru) 2017-11-28
RU2016118282A3 RU2016118282A3 (enExample) 2018-06-18
RU2695358C2 true RU2695358C2 (ru) 2019-07-23

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016118282A RU2695358C2 (ru) 2013-10-23 2014-10-22 Соединения для предотвращения и лечения нейродегенеративных заболеваний и боли

Country Status (14)

Country Link
US (1) US10301348B2 (enExample)
EP (1) EP3060566B1 (enExample)
JP (1) JP6534997B2 (enExample)
KR (1) KR102313314B1 (enExample)
CN (1) CN106414456B (enExample)
AU (1) AU2014340114B2 (enExample)
BR (1) BR112016008901B1 (enExample)
CA (1) CA2927699C (enExample)
IL (1) IL245103B (enExample)
MX (1) MX367707B (enExample)
RU (1) RU2695358C2 (enExample)
SG (1) SG11201603063WA (enExample)
WO (1) WO2015061426A1 (enExample)
ZA (1) ZA201603118B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792261A1 (ru) * 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
US11753432B2 (en) 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
CN119384282A (zh) * 2022-02-10 2025-01-28 周美吟 治疗脊髓损伤的方法及用于其中的组合物
CN119630406A (zh) * 2022-07-07 2025-03-14 周美吟 治疗思觉失调症的方法及用于其中的组合物
CN120548177A (zh) * 2022-12-29 2025-08-26 周美吟 治疗睡眠障碍的方法及用于其中的组合物
WO2024196760A1 (en) * 2023-03-17 2024-09-26 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
EA012703B1 (ru) * 2002-08-21 2009-12-30 Глэксо Груп Лимитед Производные пиримидина и их применение в качестве модуляторов cb2
US20120295863A1 (en) * 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
JP6208693B2 (ja) 2012-02-09 2017-10-04 ブランドバンプス，エルエルシー 改良されたグリップを有する装飾された検知可能な警告パネル

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
EA012703B1 (ru) * 2002-08-21 2009-12-30 Глэксо Груп Лимитед Производные пиримидина и их применение в качестве модуляторов cb2
US20120295863A1 (en) * 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical book on line, CAS RN 214759-22-5 (2008 г) и 79387-71-6 (2010 г). *
Wang J. et al, Journal of medicinal chemistry, 19.04.2007, vol. 50, No 8, 1828-1839. GONCALVES N et al, Annals of Neurology, 2013, vol. 73, No5, 655-666. *

Also Published As

Publication number Publication date
MX2016005174A (es) 2016-08-11
BR112016008901B1 (pt) 2022-08-23
US10301348B2 (en) 2019-05-28
AU2014340114B2 (en) 2018-10-18
NZ719740A (en) 2021-02-26
CA2927699A1 (en) 2015-04-30
EP3060566A4 (en) 2017-06-14
JP2016535019A (ja) 2016-11-10
WO2015061426A1 (en) 2015-04-30
RU2016118282A (ru) 2017-11-28
EP3060566A1 (en) 2016-08-31
RU2016118282A3 (enExample) 2018-06-18
ZA201603118B (en) 2019-04-24
CN106414456A (zh) 2017-02-15
CN106414456B (zh) 2018-12-14
CA2927699C (en) 2022-07-05
BR112016008901A2 (pt) 2020-05-12
US20160264613A1 (en) 2016-09-15
IL245103B (en) 2019-02-28
IL245103A0 (en) 2016-06-30
KR20160086852A (ko) 2016-07-20
AU2014340114A1 (en) 2016-05-26
MX367707B (es) 2019-09-03
EP3060566B1 (en) 2018-09-05
KR102313314B1 (ko) 2021-10-19
SG11201603063WA (en) 2016-05-30
JP6534997B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
EP3781564B1 (en) Pyridazine derivatives for the treatment of cancer
JP6534997B2 (ja) 神経変性疾患及び疼痛の予防及び治療における使用のための化合物
US11939319B2 (en) Pyridinyl and pyrazinyl-(asa)indolsulfonamides
JP6997870B2 (ja) Ｆｘｒ受容体刺激薬
CN104619691B (zh) 能够调节t-细胞应答的杂环及其使用方法
Zhang et al. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways
JP6991993B2 (ja) 痛覚過敏を治療する方法
CN112057443B (zh) 苯磺酰胺类化合物的医药用途及其药物组合物
TW202140437A (zh) Sarm1抑制劑
EP3810587A1 (en) Substituted alkoxypyridinyl indolsulfonamides
RU2709473C9 (ru) Тиофеновое соединение, способ его получения и его фармацевтическое применение
CA3015947A1 (en) Bicyclic compounds for diagnosis and therapy of alpha-synuclein associated disorders
CN118108716A (zh) 苯并噻吩类化合物及其制备方法和用途
CN117279636A (zh) 用于调节强直性肌营养不良1型的方法和化合物
ES2950348T3 (es) Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
US12006321B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
CA3143196A1 (en) Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
TWI650328B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
CN112218878A (zh) Ntcp抑制剂
TWI668007B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
WO2024080509A1 (ko) Igf-1 수용체 결합 압타머 및 이의 용도
JP2023543089A (ja) 炎症性障害および自己免疫障害の治療のためのラベキシモド（ｒａｂｅｘｉｍｏｄ）のチオノエステル誘導体
HK1196035B (en) Opioid receptor ligands and methods of using and making same
CN106279177A (zh) 氨基四氢吡喃衍生物作为二肽基肽酶-iv抑制剂